Other equities analysts have also issued research reports about the company. JPMorgan Chase & Co. set a €85.00 ($104.94) price target on MorphoSys and gave the stock a buy rating in a research report on Wednesday, November 8th. HSBC set a €64.00 ($79.01) price objective on shares of MorphoSys and gave the stock a sell rating in a research note on Friday, January 19th. Deutsche Bank set a €90.00 ($111.11) price objective on shares of MorphoSys and gave the stock a buy rating in a research note on Wednesday, November 8th. Berenberg Bank set a €85.00 ($104.94) price objective on shares of MorphoSys and gave the stock a buy rating in a research note on Thursday, December 7th. Finally, Independent Research set a €93.00 ($114.81) price objective on shares of MorphoSys and gave the stock a buy rating in a research note on Friday, December 1st. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the stock. MorphoSys currently has a consensus rating of Hold and a consensus target price of €79.70 ($98.40).
MorphoSys (ETR:MOR) opened at €79.60 ($98.27) on Thursday. The stock has a market capitalization of $2,340.00 and a PE ratio of -26.98. MorphoSys has a 52-week low of €49.63 ($61.27) and a 52-week high of €87.35 ($107.84).
WARNING: This article was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this article on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The legal version of this article can be viewed at https://sportsperspectives.com/2018/03/12/morphosys-mor-given-a-86-00-price-target-at-goldman-sachs-group.html.
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.